Pfizer completes FoldRx acquisition
NEW YORK Pfizer on Wednesday announced the completion of its acquisition of a privately held drug discovery and clinical development company.
FoldRx now is a wholly owned subsidiary of Pfizer, Pfizer said. FoldRx's portfolio includes clinical and preclinical programs for investigational compounds to treat diseases caused by protein misfolding, which increasingly is recognized as an underlying cause in many chronic degenerative diseases.
The acquisition was announced Sept. 1.